Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.
SAR, SARS Pneumonia
About this trial
This is an interventional treatment trial for SAR
Eligibility Criteria
Inclusion Criteria:
- Admitted to the Respiratory or Internal medicine Units of Santiago hospital (HUA) due to pneumonia.
- Vitamin D deficiency (25(OH) defined by blood levels below 30 mg/ml.
- Possibility for observation during the treatment period.
- Signing of written consent (oral informed consent exceptionally).
- Positive PCR for diagnosis of sars-cov2 infection
Exclusion Criteria:
- Patients taking any type of vitamin D supplement.
- Patients with hypoparathyroidism.
- Pregnant or lactating women.
- Patients in whom the administration of vitamin D is formally contraindicated (see annex VI).
- Patients who at time of inclusion, cannot take vitamin D orally.
Sites / Locations
- Joaquín Durán Cantolla
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
D VITAMIN GROUP
PLACEBO GROUP
The administration of vitamin D will be carried out using the following treatment scheme: If vitamin D deficiency (< 30 ng/ml) treatment with 2 capsules of 0.266 mg If vitamin D deficiency (< 40 ng/ml): treatment with 1 capsule of 0.266 mg Blood levels of vitamin D will be determined on day 1, 4, 7 and 14. Based on the results from day 14, a new determination is recommended 4 weeks after starting treatment with the primary care physician who will decide whether to continue or interrupt the treatment. This phase will be carried out outside of the study. In addition, the product should only be administered, if blood calcium and phosphorus levels are within normal limits, as well as if the creatinuria/calciuria ratio is within normal ranges.
The procedure will be the same as in the experimental group but instead of the active component, patients will take placebo capsules exactly the same as above but without the active component.